Behavioral Therapy Development for Methamphetamine Abuse

甲基苯丙胺滥用的行为疗法开发

• 批准号: 6892987
• 负责人: JAMES PECK
• 金额: $ 19.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6892987
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; behavioral /social science research tag; bisexual; blood tests; clinical research; cognitive behavior therapy; emotions; high risk behavior /lifestyle; homosexuals; human subject; lifestyle; male; methamphetamine; neuropsychological tests; patient oriented research; quality of life; questionnaires; self help; sex behavior; sexually transmitted diseases; substance abuse related disorder; therapy compliance; therapy design /development

DESCRIPTION (provided by applicant): This application is in response to NIDA's program announcement, PA-03-126, "Behavioral Therapies Development Program." In Los Angeles and other West Coast cities, methamphetamine use and corresponding STD transmission behaviors are central to the continuing HIV epidemic. Methamphetamine-using gay and bisexual men (GBM) who receive medical care for HIV disease are increasingly of concern to their medical care providers due to problematic drug use behaviors, associated sexual risk behaviors, and the impact of these on their HIV disease. Development of effective behavioral drug abuse treatment for methamphetamine-abusing GBM that is delivered in HIV medical care settings represents a novel "prevention for positives" intervention. Treatment-influenced reductions in methamphetamine use in this high-risk group would: decrease drug-associated problems with HIV medication adherence (and concomitant decreases in viral load); decrease drug-associated HIV transmission behaviors with unknown or anonymous partners; and decrease likelihood of sexually transmitted infections and potential superinfection with HIV. This early therapy development application (Stage I) seeks to adapt/develop a behavioral treatment for this purpose that refines our gay culture-specific cognitive-behavioral intervention (GCBT) and incorporates evidence-based elements of interventions shown effective in increasing HIV medication adherence and decreasing HIV risk behaviors. Specific aims of this project are consistent with Phase I behavioral therapy development, i.e., to (1) conduct research on the development, refinement, and pilot testing of this behavioral therapy by adapting our existing GCBT for use with HIV-infected GBM receiving HIV medical care and evaluate the feasibility of its use when delivered in the HIV care clinic; and (2) to gather estimates of the size of the signal for this adapted therapy. The project evaluates drug use, sexual risk, and HIV medication adherence behaviors for 25 treatment-seeking methamphetamine-using HIV+ GBM and 25 methamphetamine-using HIV+ GBM non-treatment-seeking men, measured at baseline through 6- month evaluations. Effectiveness data from this research will be used to inform the continued Stage II development of this intervention.

描述（由申请人提供）：此申请是响应NIDA的计划公告，PA-03-126，“行为疗法开发计划”。在洛杉矶和其他西海岸城市，甲基苯丙胺的使用和相应的性病传播行为对于持续的HIV流行是核心。 由于有问题的药物使用行为，相关的性风险行为以及这些对艾滋病毒疾病的影响，甲基苯丙胺的同性恋和双性恋男性（GBM）越来越关注其医疗服务提供者。 开发有效的甲基苯丙胺滥用GBM的行为滥用治疗，该治疗在HIV医疗环境中提供的GBM代表了一种新颖的“预防阳性”干预措施。 在这一高危组中，甲基苯丙胺使用的降低会减少：减少与药物相关的HIV药物依从性问题（病毒载量降低）；与未知或匿名伴侣减少与药物相关的HIV传播行为；并降低性传播感染的可能性和艾滋病毒的潜在末期感染。 这种早期的治疗开发应用程序（I阶段）试图为此目的适应/开发行为治疗，以完善我们的同性恋文化特异性认知行为干预（GCBT），并纳入了基于证据的干预措施，显示出有效的艾滋病毒药物依从性和降低HIV风险行为。 该项目的具体目的与I期行为疗法的发展一致，即（1）通过调整我们现有的GCBT与HIV感染的GBM接收HIV医疗保健并评估其在HIV Care Care临床中的可行性来对这种行为疗法进行开发，改进和试点测试进行研究； （2）收集这种适应治疗的信号大小的估计。该项目评估了25种寻求治疗的甲基苯丙胺的HIV+ GBM和25种使用甲基苯丙胺的HIV+ GBM的甲基苯丙胺的使用，性风险和HIV药物依从性行为，在基线上以基线为基础，直到6个月。 这项研究的有效性数据将用于告知该干预措施的持续第二阶段开发。